Introduction {#s1}
============

Gaucher\'s disease (GD) is a rare genetic disease in which fatty substances accumulate in cells and certain organs (James et al., [@B12]). It is a common lysosomal storage disorder and results from an inborn deficiency of the enzyme glucocerebrosidase (also known as acid β-glucosidase). This enzyme is responsible for glucocerebroside (glucosylceramide) degradation. The accumulation of undegraded substrate generally happens because of enzyme deficiency, mainly within cells of the macrophage lineage or monocyte, and it is responsible for the clinical manifestations of the disease (Beutler and Grabowski, [@B3]). This glucosylceramide degrading enzyme is encoded by a gene named GBA, which is 7.6 kb in length and located in 1q21 locus. Recessive mutation in GBA gene affects both males and females (Horowitz et al., [@B10]; Zimran et al., [@B26]; Winfield et al., [@B25]). GBA protein is 497 amino acids long with the molecular weight of 55.6 KD. GBA enzyme catalyses the breakdown of glucosylceramide, a cell membrane constituent of white blood cells and red blood cells. The macrophages fail to eliminate the waste product and results in accumulation of lipids in fibrils and this turn into Gaucher cells (Aharon et al., [@B1]). GD can be classified into three classes namely types 1, 2, and 3. In type 1, Glycosylceramide accumulate in visceral organs whereas in type 2 and 3, the accumulation is in the central nervous system (Grabowski, [@B9]).

The international disease frequency of GD is 200,000 except for areas of the world with large Ashkenazi Jewish populations where 60% of the patients are estimated to be homozygous, which accounts for 75% of disease alleles (Pilar et al., [@B20]). Almost 300 unique mutations have been reported in the GBA gene, with distribution that spans the entire gene. These include 203 missense mutations, 18 nonsense mutations, 36 small insertions or deletions that lead to frameshift or in-frame alterations, 14 splice junction mutations and 13 complex alleles carrying two or more mutations (Hruska et al., [@B11]). The single nucleotide variations in the genome that occur at a frequency of more than 1% are referred as single nucleotide polymorphisms (SNPs) and in the human genome, SNPs occur in just about every 3000 base pairs (Cargill et al., [@B5]).

Nearly 200 mutations in the GBA gene have been described in patients with GD types 1, 2, and 3 (Jmoudiak and Futerman, [@B13]). L444P mutation was identified in GBA gene in patients with GD types 1, 2, and 3. The L444P substitution is one of the major SNP associated with the GBA gene. D409H, A456P, and V460V mutations were also identified in patients with GD (Tsuji et al., [@B23]; Latham et al., [@B15]). Previous findings have shown that, in 60 patients with types 1 and 3, the most common Gaucher mutations identified were N370S, L444P, and R463C. (Sidransky et al., [@B21]). The other mutation E326K had been identified in patients with all three types of GD, but in each instance it was found on the same allele with another GBA mutation. Also, Park et al. identified the E326K allele in 1.3% of patients with GD and in 0.9% of controls, indicating that it is a polymorphism (Park et al., [@B19]).

The harmful SNPs for the GBA gene have not been predicted to date *in silico*. Therefore we designed a strategy for analyzing the entire GBA coding region. Different algorithms such as SIFT (Ng and Henikoff, [@B18]), MutPred (Li et al., [@B16]), nsSNP Analyzer (Bao et al., [@B2]), PANTHER (Mi et al., [@B17]), PMUT (Costa et al., [@B8]), PROVEAN (Choi et al., [@B6]), and SNPs&GO (Calabrese et al., [@B4]) were utilized to predict high-risk nonsynonymous single nucleotide polymorphisms (nsSNPs) in coding regions that are likely to have an effect on the function and structure of the protein.

Materials and methods {#s2}
=====================

Data set
--------

SNPs associated with GBA gene were retrieved from the single nucleotide polymorphism database (dbSNP) (<http://www.ncbi.nlm.nih.gov/snp/>), and are commonly referred by their reference sequence IDs (rsID) (Wheeler et al., [@B24]).

Validation of tolerated and deleterious SNPs
--------------------------------------------

The type of genetic mutation that causes a single amino acid substitution (AAS) in a protein sequence is called nsSNP. An nsSNP could potentially influence the function of the protein, subsequently altering the phenotype of carrier. This protocol describes the use of the Sorting Intolerant From Tolerant (SIFT) algorithm (<http://sift.jcvi.org>) for predicting whether an AAS affects protein function. To assess the effect of a substitution, SIFT assumes that important positions in a protein sequence have been conserved throughout evolution and therefore at these positions substitutions may affect protein function. Thus, by using sequence homology, SIFT predicts the effects of all possible substitutions at each position in the protein sequence. The protocol typically takes 5--20 min, depending on the input (Kumar et al., [@B14]).

Prediction of harmful mutations
-------------------------------

MutPred (<http://mutdb.org/mutpred>) models structural features and functional sites changes between mutant sequences and wild-type sequence. These changes are expressed as probabilities of gain or loss of structure and function. The MutPred output contains a general score (*g*), i.e., the probability that the AAS is deleterious/disease-associated and top five property scores (*p*), where *p* is the *P*-value that certain structural and functional properties are impacted. Certain combinations of high values of general scores and low values of property scores are referred to as hypotheses (Li et al., [@B16]).

Identifying disease-associated nsSNPs
-------------------------------------

nsSNP Analyzer (<http://snpanalyzer.uthsc.edu>) is a tool to predict whether a nsSNP has a phenotypic effect (disease-associated vs. neutral) using a machine learning method called Random Forest, and extracting structural and evolutionary information from a query nsSNP (Bao et al., [@B2]).

Prediction of deleterious nsSNPs
--------------------------------

PANTHER (<http://pantherdb.org/tools/csnpScoreForm.jsp>) estimates the likelihood of a particular nsSNP to cause a functional impact on a protein (Thomas et al., [@B22]). It calculates the substitution position-specific evolutionary conservation (subPSEC) score based on the alignment of evolutionarily related proteins. The subPSEC score is the negative logarithm of the probability ratio of the wild-type and the mutant amino acids at a particular position. The subPSEC scores are values from 0 (neutral) to about −10 (most likely to be deleterious).

Prediction of pathological mutations on proteins
------------------------------------------------

PMUT (<http://mmb2.pcb.ub.es:8080/PMut>) uses a robust methodology to predict disease-associated mutations. PMUT method is based on the use of neural networks (NNs) trained with a large database of neutral mutations (NEMUs) and pathological mutations of mutational hot spots, which are obtained by alanine scanning, massive mutation, and genetically accessible mutations. The final output is displayed as a pathogenicity index ranging from 0 to 1 (indexes \> 0.5 single pathological mutations) and a confidence index ranging from 0 (low) to 9 (high) (Costa et al., [@B7]).

Predicting the functional effect of amino acid substitutions
------------------------------------------------------------

PROVEAN (Protein Variation Effect Analyzer) (<http://provean.jcvi.org>) is a sequence based predictor that estimates the effect of protein sequence variation on protein function (Choi et al., [@B6]). It is based on a clustering method where BLAST hits with more than 75% global sequence identity are clustered together and top 30 such clusters from a supporting sequence are averaged within and across clusters to generate the final PROVEAN score. A protein variant is predicted to be "deleterious" if the final score is below a certain threshold (default is −2.5), and is predicted to be "neutral" if the score is above the threshold.

Prediction of disease related mutations
---------------------------------------

The SNPs&GO algorithms (<http://snps-and-go.biocomp.unibo.it/snps-and-go/>) predict the impact of protein variations using functional information encoded by Gene Ontology (GO) terms of the three main roots: Molecular function, Biological process, and Cellular component (Calabrese et al., [@B4]). SNPs&GO is a support vector machine (SVM) based web server to predict disease related mutations from the protein sequence, scoring with accuracy of 82% and Matthews correlation coefficient equal to 0.63. SNPs&GO collects, in a unique framework, information derived from protein sequence, protein sequence profile and protein functions.

Results {#s3}
=======

nsSNPs found by SIFT program
----------------------------

Protein sequence with mutational position and amino acid residue variants associated with 97 missense nsSNPs were submitted as input to the SIFT server, and the results are shown in Table [1](#T1){ref-type="table"}. The lower the tolerance index, the higher the functional impact a particular amino acid residue substitution is likely to have and vice versa. Among the 97 nsSNPs analyzed, 47 nsSNPs were identified to be deleterious with a tolerance index score ≤0.05 (Kumar et al., [@B14]). Among 47 deleterious nsSNPs, 25 nsSNPs were found to be highly deleterious.

###### 

**Tolerated and deleterious nsSNPs using SIFT**.

  **S. No**   **rsID**          **Alleles**   **Position**   **AA change**   **Prediction**   **Score**
  ----------- ----------------- ------------- -------------- --------------- ---------------- -----------
  1           rs121908314       L/V           371            Leu/Val         Damaging         0.04
  **2**       **rs121908313**   **F/L**       **251**        **Phe/Leu**     **Damaging**     **0.01**
  3           rs121908312       K/N           79             Lys/Asn         Tolerated        0.52
  4           rs121908311       G/S           377            Gly/Ser         Damaging         0.02
  5           rs121908310       V/F           398            Val/Phe         Damaging         0.01
  6           rs121908308       R/G           353            Arg/Gly         Tolerated        0.38
  7           rs121908307       S/T           364            Ser/Thr         Tolerated        0.12
  **8**       **rs121908306**   **C/G**       **342**        **Cys/Gly**     **Damaging**     **0.01**
  9           rs121908305       G/R           325            Gly/Arg         Tolerated        0.44
  **10**      **rs121908304**   **W/C**       **312**        **Trp/Cys**     **Damaging**     **0.00**
  11          rs121908303       F/V           216            Phe/Val         Damaging         0.00
  12          rs121908302       V/L           15             Val/Leu         Tolerated        0.07
  13          rs121908301       G/S           478            Gly/Ser         Tolerated        0.17
  14          rs121908300       Y/H           212            Tyr/His         Damaging         0.03
  15          rs121908299       P/S           122            Pro/Ser         Tolerated        0.37
  16          rs121908298       P/L           289            Pro/Leu         Tolerated        0.48
  17          rs121908297       K/Q           157            Lys/Gln         Tolerated        0.06
  **18**      **rs121908295**   **P/R**       **415**        **Pro/Arg**     **Damaging**     **0.00**
  19          rs80356773        R/H           496            Arg/His         Tolerated        0.19
  20          rs80356772        R/H           463            Arg/His         Tolerated        0.06
  **21**      **rs80356771**    **R/C**       **463**        **Arg/Cys**     **Damaging**     **0.02**
  22          rs80356769        V/L           394            Val/Leu         Damaging         0.03
  23          rs80356765        A/T           338            Ala/Thr         Tolerated        0.39
  24          rs80356763        R/L           131            Arg/Leu         Tolerated        0.24
  25          rs80205046        P/L           182            Pro/Leu         Damaging         0.00
  26          rs80116658        G/D           265            Gly/Asp         Damaging         0.00
  27          rs80020805        M/I           416            Met/Ile         Tolerated        0.42
  28          rs79945741        F/L           213            Phe/Leu         Tolerated        0.18
  **29**      **rs79796061**    **D/V**       **127**        **Asp/Val**     **Damaging**     **0.00**
  30          rs79696831        R/H           285            Arg/His         Damaging         0.00
  31          rs79653797        R/Q           120            Arg/Gln         Damaging         0.00
  32          rs79637617        P/L           122            Pro/Leu         Damaging         0.02
  33          rs79215220        P/R           266            Pro/Arg         Damaging         0.00
  34          rs79185870        F/L           417            Phe/Leu         Damaging         0.01
  35          rs78973108        R/Q           257            Arg/Gln         Tolerated        0.05
  36          rs78911246        G/V           189            Gly/Val         Damaging         0.02
  37          rs78802049        D/E           409            Asp/Glu         Tolerated        0.32
  38          rs78769774        R/Q           48             Arg/Gln         Tolerated        0.06
  39          rs78715199        D/E           380            Asp/Glu         Damaging         0.00
  **40**      **rs78396650**    **A/V**       **309**        **Ala/Val**     **Damaging**     **0.00**
  41          rs78198234        H/R           311            His/Arg         Damaging         0.00
  42          rs78188205        A/D           318            Ala/Asp         Tolerated        0.63
  43          rs77959976        M/I           123            Met/Ile         Tolerated        1.00
  44          rs77834747        I/S           119            Ile/Ser         Tolerated        0.34
  **45**      **rs77829017**    **G/E**       **46**         **Gly/Glu**     **Damaging**     **0.01**
  46          rs77738682        N/I           392            Asn/Ile         Damaging         0.00
  **47**      **rs77451368**    **G/E**       **202**        **Gly/Glu**     **Damaging**     **0.02**
  48          rs77369218        D/V           409            Asp/Val         Tolerated        0.06
  49          rs77321207        Y/C           395            Tyr/Cys         Damaging         0.00
  50          rs77284004        D/A           380            Asp/Ala         Damaging         0.00
  51          rs77035024        F/L           411            Phe/Leu         Tolerated        0.30
  52          rs77019233        N/K           117            Asn/Lys         Tolerated        0.21
  **53**      **rs76910485**    **P/L**       **391**        **Pro/Leu**     **Damaging**     **0.00**
  54          rs76763715        N/S           370            Asn/Ser         Damaging         0.05
  55          rs76763715        N/T           370            Asn/Thr         Damaging         0.04
  56          rs76539814        T/I           323            Thr/Ile         Tolerated        0.48
  **57**      **rs76228122**    **Y/C**       **363**        **Tyr/Cys**     **Damaging**     **0.00**
  **58**      **rs76026102**    **Y/C**       **205**        **Tyr/Cys**     **Damaging**     **0.00**
  **59**      **rs76014919**    **W/C**       **378**        **Trp/Cys**     **Damaging**     **0.00**
  60          rs75954905        F/L           37             Phe/Leu         Tolerated        0.30
  61          rs75671029        D/N           443            Asp/Asn         Tolerated        0.93
  62          rs75636769        A/E           190            Ala/Glu         Tolerated        1.00
  **63**      **rs75564605**    **I/T**       **402**        **Ile/Thr**     **Damaging**     **0.04**
  64          rs75548401        T/M           369            Thr/Met         Tolerated        0.08
  **65**      **rs75528494**    **S/R**       **366**        **Ser/Arg**     **Damaging**     **0.03**
  66          rs75385858        N/T           396            Asn/Thr         Damaging         0.00
  **67**      **rs75243000**    **F/S**       **397**        **Phe/Ser**     **Damaging**     **0.02**
  68          rs75090908        D/E           399            Asp/Glu         Tolerated        0.17
  69          rs74979486        R/Q           359            Arg/Gln         Tolerated        0.05
  70          rs74953658        D/E           24             Asp/Glu         Damaging         0.01
  **71**      **rs74752878**    **Y/C**       **418**        **Tyr/Cys**     **Damaging**     **0.00**
  72          rs74731340        S/N           271            Ser/Asn         Tolerated        0.26
  **73**      **rs74598136**    **P/L**       **401**        **Pro/Leu**     **Damaging**     **0.00**
  74          rs74500255        F/Y           216            Phe/Tyr         Tolerated        0.34
  **75**      **rs74462743**    **G/E**       **195**        **Gly/Glu**     **Damaging**     **0.00**
  **76**      **rs61748906**    **W/R**       **184**        **Trp/Arg**     **Damaging**     **0.00**
  77          rs11558184        R/Q           353            Arg/Gln         Tolerated        0.59
  78          rs2230288         E/K           326            Glu/Lys         Tolerated        0.86
  79          rs1141820         H/R           60             His/Arg         Tolerated        0.54
  80          rs1141818         H/Y           60             His/Tyr         Tolerated        0.09
  81          rs1141815         M/T           53             Met/Thr         Tolerated        0.59
  **82**      **rs1141814**     **R/W**       **48**         **Arg/Trp**     **Damaging**     **0.00**
  83          rs1141812         R/S           44             Arg/Ser         Tolerated        0.14
  84          rs1141811         T/I           43             Thr/Ile         Damaging         0.01
  **85**      **rs1141811**     **T/R**       **43**         **Thr/Arg**     **Damaging**     **0.02**
  86          rs1141808         E/K           41             Glu/Lys         Tolerated        0.52
  87          rs1141804         S/G           16             Ser/Gly         Tolerated        1.00
  88          rs1141802         L/S           15             Leu/Ser         Tolerated        0.63
  89          rs1064651         D/H           409            Asp/His         Tolerated        0.05
  90          rs1064648         R/H           329            Arg/His         Tolerated        0.17
  91          rs1064644         S/P           196            Ser/Pro         Tolerated        0.17
  92          rs421016          L/P           444            Leu/Pro         Damaging         0.00
  93          rs381737          F/I           213            Phe/Ile         Tolerated        0.18
  94          rs381427          V/E           191            Val/Glu         Tolerated        0.16
  95          rs381427          V/G           191            Val/Gly         Tolerated        0.16
  96          rs368060          A/P           456            Ala/Pro         Tolerated        0.09
  97          rs364897          N/S           188            Asn/Ser         Tolerated        0.17

The consensus SNPs are shown in bold.

Validation of harmful mutations
-------------------------------

The MutPred score is the probability that an AAS is deleterious/disease-associated. A missense mutation with a MutPred score \>0.5 could be considered as "harmful," while a MutPred score \>0.75 should be considered a high confidence "harmful" prediction (Li et al., [@B16]). Among the 47 deleterious nsSNPs, 8 were found to be harmful mutations with a score of \>0.5 and \<0.75 and 38 were found to be high confidence (highly harmful) mutations and 1 nsSNP found to be normal with the score of 0.193 (Table [2](#T2){ref-type="table"}).

###### 

**Prediction of functional effects of nsSNPs using MutPred**.

  **S. No**   **rsID**          **Alleles**   **Position**   **AA change**   **MutPred prediction**   **Score**
  ----------- ----------------- ------------- -------------- --------------- ------------------------ -----------
  1           rs121908314       L/V           371            Leu/val         High confidence          0.824
  **2**       **rs121908313**   **F/L**       **251**        **Phe/Leu**     **High confidence**      **0.778**
  3           rs121908311       G/S           377            Gly/Ser         Neutral                  0.193
  4           rs121908310       V/F           298            Val/Phe         High confidence          0.765
  **5**       **rs121908306**   **C/G**       **342**        **Cys/Gly**     **High confidence**      **0.792**
  **6**       **rs121908304**   **W/C**       **312**        **Trp/Cys**     **Harmful mutation**     **0.735**
  7           rs121908303       F/V           216            Phe/Val         High confidence          0.879
  8           rs121908300       Y/H           212            Tyr/His         High confidence          0.82
  **9**       **rs121908295**   **P/R**       **415**        **Pro/Arg**     **High confidence**      **0.914**
  **10**      **rs80356771**    **R/C**       **463**        **Arg/Cys**     **Harmful mutation**     **0.664**
  11          rs80356769        V/L           394            Val/Leu         High confidence          0.794
  12          rs80205046        P/L           182            Pro/Leu         High confidence          0.892
  13          rs80116658        G/D           265            Gly/Asp         High confidence          0.963
  **14**      **rs79796061**    **D/V**       **127**        **Asp/Val**     **High confidence**      **0.754**
  15          rs79696831        R/H           285            Arg/His         High confidence          0.884
  16          rs79653797        R/Q           120            Arg/Gln         High confidence          0.902
  17          rs79637617        P/L           122            Pro/Leu         High confidence          0.835
  18          rs79215220        P/R           166            Pro/Arg         High confidence          0.836
  19          rs79185870        F/L           417            Phe/Leu         High confidence          0.905
  20          rs78911246        G/V           189            Gly/Val         Harmful mutation         0.713
  21          rs78715199        D/E           380            Asp/Glu         High confidence          0.837
  **22**      **rs78396650**    **A/V**       **309**        **Ala/Val**     **High confidence**      **0.776**
  23          rs78198234        H/R           311            His/Arg         High confidence          0.873
  **24**      **rs77829017**    **G/E**       **46**         **Gly/Glu**     **High confidence**      **0.856**
  25          rs77738682        N/I           392            Asn/Ile         High confidence          0.814
  **26**      **rs77451368**    **G/E**       **202**        **Gly/Glu**     **Harmful mutation**     **0.676**
  27          rs77321207        Y/C           304            Tyr/Cys         High confidence          0.909
  28          rs77284004        D/A           380            Asp/Ala         High confidence          0.872
  **29**      **rs76910485**    **P/L**       **391**        **Pro/Leu**     **High confidence**      **0.889**
  30          rs76763715        N/S           370            Ans/Ser         High confidence          0.876
  31          rs76763715        N/T           370            Asn/Thr         High confidence          0.89
  **32**      **rs76228122**    **Y/C**       **363**        **Tyr/Cys**     **High confidence**      **0.93**
  **33**      **rs76026102**    **Y/C**       **205**        **Tyr/Cys**     **High confidence**      **0.857**
  **34**      **rs76014919**    **W/C**       **378**        **Trp/Cys**     **High confidence**      **0.842**
  **35**      **rs75564605**    **I/T**       **402**        **IleThr**      **High confidence**      **0.838**
  **36**      **rs75528494**    **S/R**       **366**        **Ser/Arg**     **Harmful mutation**     **0.681**
  37          rs75385858        N/T           396            Asn/Thr         High confidence          0.848
  **38**      **rs75243000**    **F/S**       **397**        **Phe/Ser**     **Harmful mutation**     **0.724**
  39          rs74953658        D/E           24             Asp/Glu         High confidence          0.818
  **40**      **rs74752878**    **Y/C**       **418**        **Tyr/Cys**     **High confidence**      **0.872**
  **41**      **rs74598136**    **P/L**       **401**        **Pro/Leu**     **High confidence**      **0.888**
  **42**      **rs74462743**    **G/E**       **195**        **Gly/Glu**     **High confidence**      **0.859**
  **43**      **rs61748906**    **W/R**       **184**        **Trp/Arg**     **High confidence**      **0.902**
  **44**      **rs1141814**     **R/W**       **48**         **Arg/Trp**     **High confidence**      **0.804**
  45          rs1141811         T/I           43             Thr/Ile         Harmful mutation         0.504
  **46**      **rs1141811**     **T/R**       **43**         **Thr/Arg**     **Harmful mutation**     **0.579**
  47          rs421016          L/P           444            Leu/Pro         High confidence          0.899

The consensus SNPs are shown in bold.

Disease-associated nsSNPs
-------------------------

Out of 47 deleterious nsSNPs, 43 were found to be a disease causing nsSNPs and 4 were found to be neutral nsSNPs (Table [3](#T3){ref-type="table"}).

###### 

**The results from nsSNP Analyzer, PMUT, PROVEAN, and SNPs&GO**.

  **S. No**   **rsID**          **Allele**   **Position**   **AA change**   **nsSNP Analyzer**   **PMUT**           **PROVEAN**   **SNPs&GO**       
  ----------- ----------------- ------------ -------------- --------------- -------------------- ------------------ ------------- ----------------- -------------
  1           rs121908314       L/V          371            Leu/val         Neutral              Neutral            −2.331        Neutral           Disease
  **2**       **rs121908313**   **F/L**      **251**        **Phe/Leu**     **Disease**          **Pathological**   **−4.567**    **Deleterious**   **Disease**
  3           rs121908311       G/S          377            Gly/Ser         Disease              Neutral            −5.128        Deleterious       Disease
  4           rs121908310       V/F          398            Val/Phe         Disease              Neutral            −4.185        Deleterious       Disease
  **5**       **rs121908306**   **C/G**      **342**        **Cys/Gly**     **Disease**          **Pathological**   **−11.467**   **Deleterious**   **Disease**
  **6**       **rs121908304**   **W/C**      **312**        **Trp/Cys**     **Disease**          **Pathological**   **−12.258**   **Deleterious**   **Disease**
  7           rs121908303       F/V          216            Phe/Val         Disease              Neutral            −7            Deleterious       Disease
  8           rs121908300       Y/H          212            Tyr/His         Disease              Neutral            −4.267        Deleterious       Disease
  **9**       **rs121908295**   **P/R**      **415**        **Pro/Arg**     **Disease**          **Pathological**   **−8.793**    **Deleterious**   **Disease**
  **10**      **rs80356771**    **R/C**      **463**        **Arg/Cys**     **Disease**          **Pathological**   **−5.279**    **Deleterious**   **Disease**
  11          rs80356769        V/L          394            Val/Leu         Neutral              Neutral            −2.031        Neutral           Disease
  12          rs80205046        P/L          182            Pro/Leu         Disease              Neutral            −9.917        Deleterious       Disease
  13          rs80116658        G/D          265            Gly/Asp         Disease              Neutral            −6.442        Deleterious       Disease
  **14**      **rs79796061**    **D/V**      **127**        **Asp/Val**     **Disease**          **Pathological**   **−8.625**    **Deleterious**   **Disease**
  15          rs79696831        R/H          285            Arg/His         Disease              Neutral            −4.792        Deleterious       Disease
  16          rs79653797        R/Q          120            Arg/Gln         Disease              Neutral            −3.641        Deleterious       Disease
  17          rs79637617        P/L          122            Pro/Leu         Disease              Neutral            −9.265        Deleterious       Disease
  18          rs79215220        P/R          266            Pro/Arg         Disease              Neutral            −8.275        Deleterious       Disease
  19          rs79185870        F/L          417            Phe/Leu         Disease              Neutral            −5.095        Deleterious       Disease
  20          rs78911246        G/V          189            Gly/Val         Disease              Neutral            −6.4          Deleterious       Disease
  21          rs78715199        D/E          380            Asp/Glu         Neutral              Neutral            −3.797        Deleterious       Disease
  **22**      **rs78396650**    **A/V**      **309**        **Ala/Val**     **Disease**          **Pathological**   **−3.533**    **Deleterious**   **Disease**
  23          rs78198234        H/R          311            His/Arg         Disease              Neutral            −7.667        Deleterious       Disease
  **24**      **rs77829017**    **G/E**      **46**         **Gly/Glu**     **Disease**          **Pathological**   **−5.925**    **Deleterious**   **Disease**
  25          rs77738682        N/I          392            Asn/Ile         Disease              Neutral            −7.593        Deleterious       Disease
  **26**      **rs77451368**    **G/E**      **202**        **Gly/Glu**     **Disease**          **Pathological**   **−5.178**    **Deleterious**   **Disease**
  27          rs77321207        Y/C          304            Tyr/Cys         Disease              Neutral            −8.358        Deleterious       Disease
  28          rs77284004        D/A          380            Asp/Ala         Disease              Neutral            −7.593        Deleterious       Disease
  **29**      **rs76910485**    **P/L**      **391**        **Pro/Leu**     **Disease**          **Pathological**   **−9.269**    **Deleterious**   **Disease**
  30          rs76763715        N/S          370            Ans/Ser         Neutral              Neutral            −2.128        Neutral           Disease
  31          rs76763715        N/T          370            Asn/Thr         Disease              Neutral            −3.062        Deleterious       Disease
  **32**      **rs76228122**    **Y/C**      **363**        **Tyr/Cys**     **Disease**          **Pathological**   **−8.492**    **Deleterious**   **Disease**
  **33**      **rs76026102**    **Y/C**      **205**        **Tyr/Cys**     **Disease**          **Pathological**   **−7.552**    **Deleterious**   **Disease**
  **34**      **rs76014919**    **W/C**      **378**        **Trp/Cys**     **Disease**          **Pathological**   **−12.306**   **Deleterious**   **Disease**
  **35**      **rs75564605**    **I/T**      **402**        **IleThr**      **Disease**          **Pathological**   **−4.363**    **Deleterious**   **Disease**
  **36**      **rs75528494**    **S/R**      **366**        **Ser/Arg**     **Disease**          **Pathological**   **−2.806**    **Deleterious**   **Disease**
  37          rs75385858        N/T          396            Asn/Thr         Disease              Neutral            −5.562        Deleterious       Disease
  **38**      **rs75243000**    **F/S**      **397**        **Phe/Ser**     **Disease**          **Pathological**   **−4.782**    **Deleterious**   **Disease**
  39          rs74953658        D/E          24             Asp/Glu         Disease              Neutral            −3.037        Deleterious       Disease
  **40**      **rs74752878**    **Y/C**      **418**        **Tyr/Cys**     **Disease**          **Pathological**   **−8.526**    **Deleterious**   **Disease**
  **41**      **rs74598136**    **P/L**      **401**        **Pro/Leu**     **Disease**          **Pathological**   **−8.136**    **Deleterious**   **Disease**
  **42**      **rs74462743**    **G/E**      **195**        **Gly/Glu**     **Disease**          **Pathological**   **−7.767**    **Deleterious**   **Disease**
  **43**      **rs61748906**    **W/R**      **184**        **Trp/Arg**     **Disease**          **Pathological**   **−13.028**   **Deleterious**   **Disease**
  **44**      **rs1141814**     **R/W**      **48**         **Arg/Trp**     **Disease**          **Pathological**   **−-6.879**   **Deleterious**   **Disease**
  45          rs1141811         T/I          43             Thr/Ile         Disease              Neutral            −3.515        Deleterious       Disease
  **46**      **rs1141811**     **T/R**      **43**         **Thr/Arg**     **Disease**          **Pathological**   **−2.557**    **Deleterious**   **Disease**
  47          rs421016          L/P          444            Leu/Pro         Disease              Neutral            −4.995        Deleterious       Disease

The consensus SNPs are shown in bold.

Validation by panther
---------------------

The protein sequence was given as input and analyzed for the deleterious effect on protein function. The subPSEC scores are values from 0 (neutral) to about −10 (deleterious) (Thomas et al., [@B22]). Out of 47 deleterious nsSNPs, 8 were found to be more than −6 (highly deleterious) and rest were found to be less deleterious. The mutant with a greater *P*~deleterious~ tends to have more severe destructions in function. It was found that 32 out of 47 deleterious nsSNPs scored greater than 3 and rests were below the damage threshold (Table [4](#T4){ref-type="table"}).

###### 

**Mutant scores from PANTHER**.

  **S. NO**   **rsID**          **Alleles**   **Position**   **AA change**   **subPSEC**    **P~deleterious~**
  ----------- ----------------- ------------- -------------- --------------- -------------- --------------------
  1           rs121908314       L/V           371            Leu/val         −3.34802       0.58614
  **2**       **rs121908313**   **F/L**       **251**        **Phe/Leu**     **−2.59088**   **0.39912**
  3           rs121908311       G/S           377            Gly/Ser         −5.35062       0.91298
  4           rs121908310       V/F           398            Val/Phe         −3.36629       0.59056
  **5**       **rs121908306**   **C/G**       **342**        **Cys/Gly**     **−3.57193**   **0.63921**
  **6**       **rs121908304**   **W/C**       **312**        **Trp/Cys**     **−2.59838**   **0.40092**
  7           rs121908303       F/V           216            Phe/Val         −4.88341       0.868
  8           rs121908300       Y/H           212            Tyr/His         −5.32716       0.9111
  **9**       **rs121908295**   **P/R**       **415**        **Pro/Arg**     **−4.90228**   **0.87015**
  **10**      **rs80356771**    **R/C**       **463**        **Arg/Cys**     **−4.45218**   **0.81033**
  11          rs80356769        V/L           394            Val/Leu         −2.8436        0.46098
  12          rs80205046        P/L           182            Pro/Leu         −6.3153        0.96495
  13          rs80116658        G/D           265            Gly/Asp         −6.00914       0.95299
  **14**      **rs79796061**    **D/V**       **127**        **Asp/Val**     **−6.29967**   **0.96442**
  15          rs79696831        R/H           285            Arg/His         −4.32962       0.79078
  16          rs79653797        R/Q           120            Arg/Gln         −4.52062       0.82063
  17          rs79637617        P/L           122            Pro/Leu         −4.49053       0.81616
  18          rs79215220        P/R           266            Pro/Arg         −6.27743       0.96365
  19          rs79185870        F/L           417            Phe/Leu         −4.16977       0.7631
  20          rs78911246        G/V           189            Gly/Val         −3.38537       0.59517
  21          rs78715199        D/E           380            Asp/Glu         −2.02623       0.27413
  **22**      **rs78396650**    **A/V**       **309**        **Ala/Val**     **−4.2769**    **0.78192**
  23          rs78198234        H/R           311            His/Arg         −4.57198       0.82807
  **24**      **rs77829017**    **G/E**       **46**         **Gly/Glu**     **−5.04065**   **0.885**
  25          rs77738682        N/I           392            Asn/Ile         −4.02188       0.73534
  **26**      **rs77451368**    **G/E**       **202**        **Gly/Glu**     **−1.32995**   **0.15842**
  27          rs77321207        Y/C           304            Tyr/Cys         −6.26737       0.96329
  28          rs77284004        D/A           380            Asp/Ala         −2.36947       0.34739
  **29**      **rs76910485**    **P/L**       **391**        **Pro/Leu**     **−6.12534**   **0.95793**
  30          rs76763715        N/S           370            Ans/Ser         −2.69603       0.42459
  31          rs76763715        N/T           370            Asn/Thr         −1.97735       0.26451
  **32**      **rs76228122**    **Y/C**       **363**        **Tyr/Cys**     **−4.75749**   **0.85289**
  **33**      **rs76026102**    **Y/C**       **205**        **Tyr/Cys**     **−5.89294**   **0.9475**
  **34**      **rs76014919**    **W/C**       **378**        **Trp/Cys**     **−5.31772**   **0.91033**
  **35**      **rs75564605**    **I/T**       **402**        **IleThr**      **−3.78009**   **0.6857**
  **36**      **rs75528494**    **S/R**       **366**        **Ser/Arg**     **−2.07688**   **0.28432**
  37          rs75385858        N/T           396            Asn/Thr         −3.61569       0.64924
  **38**      **rs75243000**    **F/S**       **397**        **Phe/Ser**     **−2.88329**   **0.47086**
  39          rs74953658        D/E           24             Asp/Glu         −4.17446       0.76395
  **40**      **rs74752878**    **Y/C**       **418**        **Tyr/Cys**     **−6.31864**   **0.96506**
  **41**      **rs74598136**    **P/L**       **401**        **Pro/Leu**     **−2.14888**   **0.2992**
  **42**      **rs74462743**    **G/E**       **195**        **Gly/Glu**     **−4.74669**   **0.85153**
  **43**      **rs61748906**    **W/R**       **184**        **Trp/Arg**     **−3.5793**    **0.64091**
  **44**      **rs1141814**     **R/W**       **48**         **Arg/Trp**     **−7.03366**   **0.9826**
  45          rs1141811         T/I           43             Thr/Ile         −4.20869       0.77007
  **46**      **rs1141811**     **T/R**       **43**         **Thr/Arg**     **−4.05221**   **0.7412**
  47          rs421016          L/P           444            Leu/Pro         −3.43747       0.60766

The consensus SNPs are shown in bold.

Functional impact of mutations on proteins
------------------------------------------

The functional impact of 47 deleterious nsSNPs in protein of GBA was analyzed using PMUT server. Of the 47 nsSNPs, 22 are classified as pathological, and the remaining were neutral (Table [3](#T3){ref-type="table"}).

Protein variation effect analysis
---------------------------------

PROVEAN predicts the effect of the variant on the biological function of the protein based on sequence homology. PROVEAN scores are classified as "deleterious" if below a certain threshold (here −2.5) and "neutral" if above it (Choi et al., [@B6]). Out of 47 nsSNPs, 44 were predicted to be "deleterious" and 3 were found to be "neutral" (Table [3](#T3){ref-type="table"}).

Prediction of disease related mutations by SNPs&GO
--------------------------------------------------

SNPs&GO is trained and tested with cross-validation procedures in which similar proteins are placed together as a dataset to calculate the *LGO* score derived from the GO data base. All 47 deleterious nsSNPs showed the disease related mutations (Table [3](#T3){ref-type="table"}).

Discussion {#s4}
==========

In the recent years, SNPs have emerged as the new generation molecular markers. The harmful SNPs for the GBA gene were never been predicted to date *in silico*. This study was designed to understand the genetic variations associated with GBA gene. We have predicted the harmful nsSNPs using SIFT, MutPred, nsSNP Analyzer, PANTHER, PMUT, PROVEAN, and SNPs&GO state of the art computational tools. Among 97 nsSNPs, 47 were found to be deleterious with a tolerance index score of ≤0.05 found by SIFT program. Among the 47 deleterious nsSNPs, 46 were found to be harmful nsSNPs found by MutPred, 43 were found to be disease causing nsSNPs by nsSNP Analyzer tool, 32 are highly deleterious found by PANTHER program, 22 are classified as pathological mutations by PMUT, 44 were predicted to be deleterious by PROVEAN server while all 47 deleterious nsSNPs showed the disease related mutations by SNPs&GO. Also, we found that SNPs&GO was most successful of all state of the art SNP prediction programs that were used for this comparative study. In this work, we found 22 nsSNPs that are common in all (SIFT, MutPred, nsSNP Analyzer, PANTHER, PMUT, PROVEAN, and SNPs&GO) prediction (Figure [1](#F1){ref-type="fig"}). These sets of 22 nsSNPs (F251L, C342G, W312C, P415R, R463C, D127V, A309V, G46E, G202E, P391L, Y363C, Y205C, W378C, I402T, S366R, F397S, Y418C, P401L, G195E, W184R, R48W, and T43R) are possibly the main targeted mutation for the GD (Tables [1](#T1){ref-type="table"}--[4](#T4){ref-type="table"}). The previous work has shown that, in 60 patients with types 1 and 3, the most common Gaucher mutations identified were L444P, N370S, and R463C. L444P was the most common mutation in GD types 1, 2, and 3 (Latham et al., [@B15]; Sidransky et al., [@B21]). In our analysis, out of 7 methods, 6 methods (Sift, MutPred, PROVEAN, PANTHER, nsSNP Analyzer, and SNPs&GO) shows L444P mutation as damaging, 3 methods shows N370S mutation as damaging and all the 7 methods shows R463C mutation as damaging. D409H, A456P, E326K, and V460V mutations were also identified in patients with GD (Tsuji et al., [@B23]; Park et al., [@B19]). In our analysis SIFT result shows D409H, A456P, and E326K mutation is the tolerated mutation. Further studies using these mutations will shed light on the genetic understanding of this major lysosomal storage disease.

![**Sets of various mutations identified using various software tools**. The respective locations of 44 amino acids responsible for all 47 mutations are shown in the sequence (center, colored in bold) and 22 common mutations are highlighted as consensus.](fgene-05-00148-g0001){#F1}
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